Synergistic growth inhibition of human hepatocellular carcinoma cells by acyclic retinoid and GW4064, a farnesoid X receptor ligand

Cancer Letters

Volumn 323, Issue 2, 2012, Pages 215-222

  Ohno, Tomohiko ^a   Shirakami, Yohei ^a   Shimizu, Masahito ^a   Kubota, Masaya ^a   Sakai, Hiroyasu ^a   Yasuda, Yoichi ^a   Kochi, Takahiro ^a   Tsurumi, Hisashi ^a   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY   (Japan)

Author keywords

Acyclic retinoid; FXR; GW4064; Hepatocellular carcinoma; RXR ; Synergism

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; ACYCLIC RETINOID; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; FARNESOID X RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PROTEIN TYROSINE PHOSPHATASE SHP; RETINOID DERIVATIVE; RETINOID X RECEPTOR ALPHA; STAT3 PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; LIVER CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL DIVISION; HUMANS; ISOXAZOLES; LIVER NEOPLASMS; PROMOTER REGIONS, GENETIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RETINOIDS;

EID: 84863094571     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.04.015     Document Type: Article

References (39)

1. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., Evans R.M. The nuclear receptor superfamily: the second decade. Cell 1995, 83:835-839.
2. Chambon P. A decade of molecular biology of retinoic acid receptors. Faseb. J. 1996, 10:940-954.
3. Altucci L., Leibowitz M.D., Ogilvie K.M., de Lera A.R., Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. Nat. Rev. Drug Discov. 2007, 6:793-810.
4. Matsushima-Nishiwaki R., Okuno M., Takano Y., Kojima S., Friedman S.L., Moriwaki H. Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid. Carcinogenesis 2003, 24:1353-1359.
5. Matsushima-Nishiwaki R., Okuno M., Adachi S., Sano T., Akita K., Moriwaki H., Friedman S.L., Kojima S. Phosphorylation of retinoid X receptor alpha at serine 260 impairs its metabolism and function in human hepatocellular carcinoma. Cancer Res. 2001, 61:7675-7682.
6. Adachi S., Okuno M., Matsushima-Nishiwaki R., Takano Y., Kojima S., Friedman S.L., Moriwaki H., Okano Y. Phosphorylation of retinoid X receptor suppresses its ubiquitination in human hepatocellular carcinoma. Hepatology 2002, 35:332-340.
7. Yoshimura K., Muto Y., Shimizu M., Matsushima-Nishiwaki R., Okuno M., Takano Y., Tsurumi H., Kojima S., Okano Y., Moriwaki H. Phosphorylated retinoid X receptor alpha loses its heterodimeric activity with retinoic acid receptor beta. Cancer Sci. 2007, 98:1868-1874.
8. Shimizu M., Takai K., Moriwaki H. Strategy and mechanism for the prevention of hepatocellular carcinoma: phosphorylated retinoid X receptor alpha is a critical target for hepatocellular carcinoma chemoprevention. Cancer Sci. 2009, 100:369-374.
9. Muto Y., Moriwaki H., Ninomiya M., Adachi S., Saito A., Takasaki K.T., Tanaka T., Tsurumi K., Okuno M., Tomita E., Nakamura T., Kojima T. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma prevention study group. New Engl. J. Med. 1996, 334:1561-1567.
10. Muto Y., Moriwaki H., Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. New Engl. J. Med. 1999, 340:1046-1047.
11. Tatebe H., Shimizu M., Shirakami Y., Sakai H., Yasuda Y., Tsurumi H., Moriwaki H. Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells. Cancer Lett. 2009, 285:210-217.
12. Suzui M., Masuda M., Lim J.T., Albanese C., Pestell R.G., Weinstein I.B. Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1. Cancer Res. 2002, 62:3997-4006.
13. Wang Y.D., Chen W.D., Moore D.D., Huang W. FXR: a metabolic regulator and cell protector. Cell Res. 2008, 18:1087-1095.
14. Huang W., Ma K., Zhang J., Qatanani M., Cuvillier J., Liu J., Dong B., Huang X., Moore D.D. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 2006, 312:233-236.
15. Yang F., Huang X., Yi T., Yen Y., Moore D.D., Huang W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 2007, 67:863-867.
16. Kim I., Morimura K., Shah Y., Yang Q., Ward J.M., Gonzalez F.J. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 2007, 28:940-946.
17. Wolfe A., Thomas A., Edwards G., Jaseja R., Guo G.L., Apte U. Increased activation of the Wnt/{beta}-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid x receptor knockout mice. J. Pharmacol. Exp. Ther. 2011, 338:12-21.
18. Obora A., Shiratori Y., Okuno M., Adachi S., Takano Y., Matsushima-Nishiwaki R., Yasuda I., Yamada Y., Akita K., Sano T., Shimada J., Kojima S., Okano Y., Friedman S.L., Moriwaki H. Synergistic induction of apoptosis by acyclic retinoid and interferon-beta in human hepatocellular carcinoma cells. Hepatology 2002, 36:1115-1124.
19. Shimizu M., Suzui M., Deguchi A., Lim J.T., Xiao D., Hayes J.H., Papadopoulos K.P., Weinstein I.B. Synergistic effects of acyclic retinoid and OSI-461 on growth inhibition and gene expression in human hepatoma cells. Clin. Cancer Res. 2004, 10:6710-6721.
20. 2 in human hepatocellular carcinoma cells. Cancer Sci. 2007, 98:431-437.
21. Tatebe H., Shimizu M., Shirakami Y., Tsurumi H., Moriwaki H. Synergistic growth inhibition by 9-cis-retinoic acid plus trastuzumab in human hepatocellular carcinoma cells. Clin. Cancer Res. 2008, 14:2806-2812.
22. Liu Y. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J. Clin. Invest. 2003, 112:1678-1687.
23. Kim I., Ahn S.H., Inagaki T., Choi M., Ito S., Guo G.L., Kliewer S.A., Gonzalez F.J. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J. Lipid Res. 2007, 48:2664-2672.
24. Giordano C., Catalano S., Panza S., Vizza D., Barone I., Bonofiglio D., Gelsomino L., Rizza P., Fuqua S.A., Ando S. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression. Oncogene 2011.
25. Swales K.E., Korbonits M., Carpenter R., Walsh D.T., Warner T.D., Bishop-Bailey D. The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res. 2006, 66:10120-10126.
26. Kaeding J., Bouchaert E., Belanger J., Caron P., Chouinard S., Verreault M., Larouche O., Pelletier G., Staels B., Belanger A., Barbier O. Activators of the farnesoid X receptor negatively regulate androgen glucuronidation in human prostate cancer LNCAP cells. Biochem. J. 2008, 410:245-253.
27. Zhao L., Wientjes M.G., Au J.L. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin. Cancer Res. 2004, 10:7994-8004.
28. Shimizu M., Yasuda Y., Sakai H., Kubota M., Terakura D., Baba A., Ohno T., Kochi T., Tsurumi H., Tanaka T., Moriwaki H. Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-db/db obese mice. BMC Cancer 2011, 11:281.
29. Shimizu M., Suzui M., Deguchi A., Lim J.T., Weinstein I.B. Effects of acyclic retinoid on growth, cell cycle control, epidermal growth factor receptor signaling, and gene expression in human squamous cell carcinoma cells. Clin. Cancer Res. 2004, 10:1130-1140.
30. Zhang Y., Xu P., Park K., Choi Y., Moore D.D., Wang L. Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation. Hepatology 2008, 48:289-298.
31. Maran R.R., Thomas A., Roth M., Sheng Z., Esterly N., Pinson D., Gao X., Zhang Y., Ganapathy V., Gonzalez F.J., Guo G.L. Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J. Pharmacol. Exp. Ther. 2009, 328:469-477.
32. Zhang Y., Soto J., Park K., Viswanath G., Kuwada S., Abel E.D., Wang L. Nuclear receptor SHP, a death receptor that targets mitochondria, induces apoptosis and inhibits tumor growth. Mol. Cell Biol. 2010, 30:1341-1356.
33. Mulholland D.J., Dedhar S., Coetzee G.A., Nelson C.C. Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know?. Endocr. Rev. 2005, 26:898-915.
34. Yamada Y., Shidoji Y., Fukutomi Y., Ishikawa T., Kaneko T., Nakagama H., Imawari M., Moriwaki H., Muto Y. Positive and negative regulations of albumin gene expression by retinoids in human hepatoma cell lines. Mol. Carcinog. 1994, 10:151-158.
35. Suzui M., Shimizu M., Masuda M., Lim J.T., Yoshimi N., Weinstein I.B. Acyclic retinoid activates retinoic acid receptor beta and induces transcriptional activation of p21(CIP1) in HepG2 human hepatoma cells. Mol. Cancer Ther. 2004, 3:309-316.
36. Shimizu M., Sakai H., Shirakami Y., Iwasa J., Yasuda Y., Kubota M., Takai K., Tsurumi H., Tanaka T., Moriwaki H. Acyclic retinoid inhibits diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BLKS/J- +(db)/+Lepr(db) mice. Cancer Prev. Res. 2011, 4:128-136.
37. Araki H., Shidoji Y., Yamada Y., Moriwaki H., Muto Y. Retinoid agonist activities of synthetic geranyl geranoic acid derivatives. Biochem. Biophys. Res. Commun. 1995, 209:66-72.
38. Sano T., Kagawa M., Okuno M., Ishibashi N., Hashimoto M., Yamamoto M., Suzuki R., Kohno H., Matsushima-Nishiwaki R., Takano Y., Tsurumi H., Kojima S., Friedman S.L., Moriwaki H., Tanaka T. Prevention of rat hepatocarcinogenesis by acyclic retinoid is accompanied by reduction in emergence of both TGF-alpha-expressing oval-like cells and activated hepatic stellate cells. Nutr. Cancer 2005, 51:197-206.
39. Fiorucci S., Cipriani S., Mencarelli A., Baldelli F., Bifulco G., Zampella A. Farnesoid X Receptor Agonist for the Treatment of Liver and Metabolic Disorders: Focus on 6-ethyl-CDCA. Mini Rev. Med. Chem. 2011, 11:753-762.